نتائج البحث - "Courvoisier, Delphine Sophie"

1

2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases

المصدر: Annals of the Rheumatic Diseases. 82(6):742-753

مصطلحات موضوعية: Antirheumatic Agents, Autoimmune Diseases, Tuberculosis, Medicin och hälsovetenskap, Klinisk medicin, Infektionsmedicin, Medical and Health Sciences, Clinical Medicine, Infectious Medicine

الوصول الحر: https://lup.lub.lu.se/record/3fc1d5cc-c2e6-445b-ad1f-13d5adc60c16Test
http://dx.doi.org/10.1136/ard-2022-223335Test

View record in SwePub

2

دورية أكاديمية

Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease.

المؤلفون: Gabay, Cem, Fautrel, Bruno, Rech, Jurgen, Spertini, Francois, Feist, Eugen, Kotter, Ina, Hachulla, Eric, Morel, Jacques, Schaeverbeke, Thierry, Hamidou, Mohamed, Martin, Thierry, Hellmich, Bernhard, Lamprecht, Peter, Schulze-Koops, Hendrik, Courvoisier Delphine, Sophie, Sleight, Andrew, Schiffrin Eduardo, Jorge

المساهمون: Inserm, Université de Lille, CHU Lille, Lille Inflammation Research International Center (LIRIC) - U995, Université Pierre et Marie Curie - Paris 6 UPMC, Lille Inflammation Research International Center - U 995 LIRIC, Université de Nantes UN, Laboratoire de Génie des Procédés et Matériaux - EA 4038 LGPM

مصطلحات موضوعية: adult onset still''s disease, inflammation, juvenile idiopathic arthritis

وصف الملف: application/rdf+xml; charset=utf-8; application/pdf

العلاقة: Annals of the Rheumatic Diseases; Ann. Rheum. Dis.; http://hdl.handle.net/20.500.12210/5082Test

الإتاحة: https://doi.org/20.500.12210/5082Test
https://hdl.handle.net/20.500.12210/5082Test

View record in BASE

3

دورية أكاديمية

Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study)

المساهمون: HUS Internal Medicine and Rehabilitation, Department of Medicine, Clinicum

مصطلحات موضوعية: Antirheumatic Agents, Arthritis, Rheumatoid, Biological Therapy, Epidemiology, 3121 General medicine, internal medicine and other clinical medicine

وصف الملف: application/pdf

العلاقة: The JAK-pot study has received unrestricted research grant from: AbbVie, Galapagos, Pfizer and Eli Lilly. BIOREG, the Austrian registry for biologicals, biosimilars and tsDMARDs in the treatment of inflammatory rheumatic diseases, is in close partnership with the Austrian Society for Rheumatology and Rehabilitation (OGR) and is supported by an unrestricted educational grant from AbbVie, Amgen, Eli Lilly, Fresenius-Kabi, Gilead, Janssen-Cilag, MSD, Pfizer, Sandoz, UCB. Clinical work in Czech Republic was partially supported by the project from the Ministry of Health for conceptual development of research organisation MZ00023728023728 (Institute of Rheumatology). BIOBADASER has received funding from Fundacion Espanola de Reumatologia, the Spanish Medicines and Health Products Agency (Agencia Espanola del Medicamento y Productos Sanitarios) and equal grants from pharmaceutical companies (AbbVie, BMS, Celltrion, Galapagos, Janssen, Lilly, MSD, Novartis, Pfizer, Regeneron, Roche, Samsung, Schering-Plough and UCB). BioRx. si has received funding for clinical research paid to Drustvo za razvoj revmatologije from AbbVie, Roche, Medis, MSD, Biogen, Amgen, Sanofi, Celgene and Pfizer. The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA) is funded by a grant from the British Society for Rheumatology (BSR). The BSR currently receives funding from AbbVie, Amgen, Celltrion Healthcare, Eli Lilly, Galapagos, Pfizer, Samsung Bioepis and Sanofi and in the past Hospira, MSD, Roche, Sandoz, SOBI and UCB. This income finances a wholly separate contract between the BSR and The University of Manchester to host the BSRBR-RA. All decisions concerning study design, data capture, analyses, interpretation and publication are made autonomously of any industrial contribution. Members of the BSRBR-RA University of Manchester team, BSR trustees, committee members and staff complete an annual declaration in relation to conflicts of interest. All relevant information regarding serious adverse events outlined in the manuscript have been reported to the appropriate pharmaceutical company as per the contractual agreements/ standard operating procedures. DANBIO was partially supported by public and private funding (AbbVie, Biogen, Bristol Myers Squibb, Eli Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, UCB). NOR-DMARD has been supported with research funding to Diakonhjemmet Hospital from AbbVie, Amgen, BMS, MSD, Novartis, Pfizer and UCB. The German RABBIT registry is currently supported by a joint, unconditional grant from AbbVie, Amgen, BMS, Celltrion, Fresenius Kabi, Galapagos, Hexal, Lilly, MSD, Pfizer, Samsung Bioepis, Sanofi Aventis, VIATRIS SANTE and UCB, and previously by Roche. REUMA. PT is supported by unrestricted grants from AbbVie, Biogen, Celgene, MSD, Roche, Sanofi and Pfizer. ROB-FIN is funded by AbbVie, Hospira, BMS, MSD, Pfizer, Roche and UCB. The Romanian Registry of Rheumatic Diseases (RRBR) uses unrestricted grants from AbbVie, Pfizer, Eli Lilly, Ewopharma, Nopvartis MSD, Roche, UCB, and BMS. Swiss Clinical Quality Management in Rheumatic Diseases (SCQM) database is sponsored by public and industrial support (http://scqm.ch/enTest/ sponsoren/).; Aymon , R , Mongin , D , Bergstra , S A , Choquette , D , Codreanu , C , De Cock , D , Dreyer , L , Elkayam , O , Huschek , D , Hyrich , K L , Iannone , F , Inanc , N , Kearsley-Fleet , L , Koca , S S , Kvien , T K , Leeb , B F , Lukina , G , Nordström , D C , Pavelka , K , Pombo-Suarez , M , Rodrigues , A , Rotar , Z , Strangfeld , A , Verschueren , P , Westermann , R , Zavada , J , Courvoisier , D S , Finckh , A & Lauper , K 2024 , ' Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study) ' , Annals of the Rheumatic Diseases , vol. 83 , no. 4 , pp. 421-428 . https://doi.org/10.1136/ard-2023-224670Test; http://hdl.handle.net/10138/574261Test; aef68eeb-ba11-470f-b986-628e05a21385; 001119185000001

الإتاحة: http://hdl.handle.net/10138/574261Test

View record in BASE

4

دورية أكاديمية

After JAK inhibitor failure:to cycle or to switch, that is the question - data from the JAK-pot collaboration of registries

المصدر: Pombo-Suarez , M , Sanchez-Piedra , C , Gómez-Reino , J , Lauper , K , Mongin , D , Iannone , F , Pavelka , K , Nordström , D C , Inanc , N , Codreanu , C , Hyrich , K L , Choquette , D , Strangfeld , A , Leeb , B F , Rotar , Z , Rodrigues , A , Kristianslund , E K , Kvien , T K , Elkayam , O , Lukina , G , Bergstra , S A , Finckh , A & Courvoisier , D S 2023 ....

مصطلحات موضوعية: Antirheumatic Agents, Arthritis, Rheumatoid, Therapeutics

وصف الملف: application/pdf

العلاقة: https://research.manchester.ac.uk/en/publications/df214c9c-735e-4049-8e99-b40d59c2dda1Test

الإتاحة: https://doi.org/10.1136/ard-2022-222835Test
https://research.manchester.ac.uk/en/publications/df214c9c-735e-4049-8e99-b40d59c2dda1Test
https://pure.manchester.ac.uk/ws/files/250115623/175.full.pdfTest
https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_starter&SrcAuth=WosAPI&KeyUT=WOS:000853823900001&DestLinkType=FullRecord&DestApp=WOSTest

View record in BASE

5

دورية أكاديمية

Effect of SARS-CoV-2 prior infection and mRNA vaccination on contagiousness and susceptibility to infection

المؤلفون: Mongin, Denis, Bürgisser, Nils, Laurie, Gustavo, Schimmel, Guillaume, Vu, Diem-Lan, Cullati, Stephane, Da Silva Mora, Lucienne, Després, Lena, Dudouit, Rachel, Hirsch, Béatrice, Müller, Barbara, Roux, Charlotte, Duc, Géraldine, Zahnd, Caroline, Caparros, Adriana Uribe, Falcone, Jean-Luc, Silva, Nuno M., Goeury, Thomas, Charpilloz, Christophe, Adamou, Silas, Brindel, Pauline, Petrucci, Roberta, Allgöwer, Andrea, Kadjangaba, Abdel, Loha, Christopher Abo, Macher, Emilie, Vassant, Marc, Donnat, Nadia, Pittet, Philippe, Joubert, Dominique, Carballido, Samia, Germain, Ariane, Bontemps, Sophie, Delaporte, Elisabeth, Genecand, Camille, Metsini, Aliki, Creac’h, Valérie, Calatraba, Virginie, Flüeli, Laura, Piccard, Hippolyte, Lebowitz, Dan, Tardin, Aglaé, Regard, Simon, Courvoisier, Delphine Sophie

المساهمون: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

المصدر: Nature Communications ; volume 14, issue 1 ; ISSN 2041-1723

مصطلحات موضوعية: General Physics and Astronomy, General Biochemistry, Genetics and Molecular Biology, General Chemistry, Multidisciplinary

الإتاحة: https://doi.org/10.1038/s41467-023-41109-9Test
https://www.nature.com/articles/s41467-023-41109-9.pdfTest
https://www.nature.com/articles/s41467-023-41109-9Test

View record in BASE

6

دورية أكاديمية

Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the ‘JAK-pot’ study)

المساهمون: Eli Lilly and Company, Galápagos, AbbVie, Pfizer

المصدر: Annals of the Rheumatic Diseases ; volume 83, issue 4, page 421-428 ; ISSN 0003-4967 1468-2060

مصطلحات موضوعية: General Biochemistry, Genetics and Molecular Biology, Immunology, Immunology and Allergy, Rheumatology

الإتاحة: https://doi.org/10.1136/ard-2023-224670Test

View record in BASE

7

دورية أكاديمية

EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology

المساهمون: Université de Genève = University of Geneva (UNIGE), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), VU University Medical Center Amsterdam, CHU Pitié-Salpêtrière AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Karolinska Institutet Stockholm, University of Manchester Manchester, Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA), Department of Genetics Cambridge, University of Cambridge UK (CAM), Center for Healthy Aging Copenhagen, Faculty of Health and Medical Sciences, University of Copenhagen = Københavns Universitet (UCPH)-University of Copenhagen = Københavns Universitet (UCPH), University of Ljubljana, Hospital Garcia de Orta (EPE), Medizinische Universität Wien = Medical University of Vienna, University of Leeds, Deutsches Rheuma-ForschungsZentrum (DRFZ), Deutsches Rheuma-ForschungsZentrum, Leiden University Medical Center (LUMC), Universiteit Leiden = Leiden University, Dpt of Clinical Immunology & Rheumatology Amsterdam, Amsterdam and Atrium Medical Center

المصدر: ISSN: 0003-4967.

مصطلحات موضوعية: [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system

العلاقة: hal-03543438; https://hal.sorbonne-universite.fr/hal-03543438Test; https://hal.sorbonne-universite.fr/hal-03543438/documentTest; https://hal.sorbonne-universite.fr/hal-03543438/file/annrheumdis-2021-221307.full.pdfTest

الإتاحة: https://doi.org/10.1136/annrheumdis-2021-221307Test
https://hal.sorbonne-universite.fr/hal-03543438Test
https://hal.sorbonne-universite.fr/hal-03543438/documentTest
https://hal.sorbonne-universite.fr/hal-03543438/file/annrheumdis-2021-221307.full.pdfTest

View record in BASE

8

دورية أكاديمية

Glucocorticoids prescribing practices in systemic sclerosis: an analysis of the EUSTAR database.

المؤلفون: Iudici, Michele, Mongin, Denis, Siegert, Elise, Carreira, Patricia E., Distler, Jörg, Henes, Jörg, Zanatta, Elisabetta, Hachulla, Eric, De Luca, Giacomo, Müller, Carolina S., Santiago, Tania, Tandaipan, José-Luis, Bianchi, Breno V., De Santis, Maria, Hoffmann-Vold, Anna-Maria, Gabrielli, Armando, Distler, Oliver, Courvoisier, Delphine Sophie

المساهمون: Université de Lille, Inserm, CHU Lille, Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

وصف الملف: application/octet-stream

العلاقة: Rheumatology; Rheumatology (Oxford); http://hdl.handle.net/20.500.12210/100739Test

الإتاحة: https://doi.org/20.500.12210/100739Test
https://hdl.handle.net/20.500.12210/100739Test

View record in BASE

9

دورية أكاديمية

2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases

المساهمون: National and Kapodistrian University of Athens (NKUA), University of Glasgow, King‘s College London, University of Liverpool, Faculty of Biology, Medicine and Health Manchester, UK, University of Manchester Manchester, Hôpitaux universitaires de Genève = University Hospitals of Geneva (HUG), Service de rhumatologie Strasbourg, Centre Hospitalier Universitaire Strasbourg (CHU Strasbourg), Les Hôpitaux Universitaires de Strasbourg (HUS)-Les Hôpitaux Universitaires de Strasbourg (HUS)-Hôpital de Hautepierre Strasbourg, Università degli Studi di Messina = University of Messina (UniMe), Medizinische Hochschule Hannover = Hannover Medical School (MHH), University Medical Center Utrecht, Nicosia General Hospital, Skane University Hospital Lund, University of Coimbra Portugal (UC), Physiologie & médecine expérimentale du Cœur et des Muscles U 1046 (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier), Semmelweis University of Medicine Budapest, Vall d’Hebron Research Institute (VHIR), Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), EULAR standing committee of People with Arthritis/Rheumatism in Europe (PARE), Università degli Studi di Modena e Reggio Emilia = University of Modena and Reggio Emilia (UNIMORE), Deutsches Rheuma-ForschungsZentrum (DRFZ), Deutsches Rheuma-ForschungsZentrum, Charité - UniversitätsMedizin = Charité - University Hospital Berlin, Aarhus University Hospital, Manchester University NHS Foundation Trust (MFT)

المصدر: ISSN: 0003-4967.

مصطلحات موضوعية: Antirheumatic Agents, Autoimmune Diseases, Tuberculosis, MESH: Adult, MESH: Antirheumatic Agents / therapeutic use, MESH: Antiviral Agents / therapeutic use, MESH: Humans, MESH: Immunosuppressive Agents / therapeutic use, MESH: Opportunistic Infections / diagnosis, MESH: Opportunistic Infections / prevention & control, MESH: Rheumatic Diseases / complications, MESH: Rheumatic Diseases / drug therapy, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases

العلاقة: hal-03840320; https://hal.science/hal-03840320Test; https://hal.science/hal-03840320/documentTest; https://hal.science/hal-03840320/file/2022%20Fragoulis%20et%20al.%202022%20EULAR.pdfTest

الإتاحة: https://doi.org/10.1136/ard-2022-223335Test
https://hal.science/hal-03840320Test
https://hal.science/hal-03840320/documentTest
https://hal.science/hal-03840320/file/2022%20Fragoulis%20et%20al.%202022%20EULAR.pdfTest

View record in BASE

10

دورية أكاديمية

Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration

المساهمون: HUS Internal Medicine and Rehabilitation, Department of Medicine, Clinicum, University of Helsinki, Reumatologian yksikkö

مصطلحات موضوعية: Epidemiology, Biological Therapy, Tumor Necrosis Factor Inhibitors, Arthritis, Rheumatoid, Therapeutics, NECROSIS-FACTOR-ALPHA, DOUBLE-BLIND, PLUS METHOTREXATE, PHASE-III, ADALIMUMAB, PLACEBO, TOFACITINIB, MONOTHERAPY, MULTICENTER, INFLIXIMAB, 3121 General medicine, internal medicine and other clinical medicine

وصف الملف: application/pdf

العلاقة: Clinical work in Czech Republic was partially supported by the project from the Ministry of Health for conceptual development of research organisation MZ00023728023728 (Institute of Rheumatology). BIOBADASER has received funding from Fundacion Espanola de Reumatologia, the Spanish Medicines and Health Products Agency (Agencia Espanola del Medicamento y Productos Sanitarios) and equal grants from pharmaceutical companies (AbbVie, BMS, Celltrion, Galapagos, Janssen, Lilly, MSD, Novartis, Pfizer, Regeneron, Roche, Samsung, Schering-Plough and UCB). BioRx.si has received funding for clinical research paid to Drustvo za razvoj revmatologije from AbbVie, Roche, Medis, MSD, Biogen, Amgen, Sanofi, Celgene and Pfizer. The British Society for Rheumatology Biologics Register in Rheumatoid Arthritis (BSRBR--RA) is funded by a grant from the British Society for Rheumatology (BSR). The BSR currently receives funding from Abbvie, Amgen, Celltrion HC, Eli Lilly, Pfizer, Samsung Bioepis, Sanofi, Sandoz and in the past Hospira, MSD, Roche, SOBI and UCB. This income finances a wholly separate contract between the BSR and The University of Manchester to host the BSRBR--RA. All decisions concerning study design, data capture, analyses, interpretation and publication are made autonomously of any industrial contribution. The BSRBR--RA would like to gratefully acknowledge the support of the National Institute for Health Research, through the Local Clinical Research Networks in England (and equivalent organisations in the devolved nations) at participating centres and the BSRBR--RA Control Centre Consortium. DANBIO was partially supported by public and private funding (AbbVie, Biogen, Bristol Myers Squibb, Eli Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, UCB). NOR--DMARD was has been supported with research funding to Diakonhjemmet Hospital from AbbVie, Amgen, BMS, MSD, Novartis, Pfizer and UCB. The RABBIT register is currently supported by an unconditional grant with equal parts from AbbVie, Amgen, BMS, Celltrion, Fresenius Kabi, Galapagos, Hexal, Lilly, MSD, Viatris, Pfizer, Roche, Samsung Bioepis, Sanofi--Aventis, and UCB. REUMA. PT supported by unrestricted grants from Abbvie, Biogen, Celgene, MSD, Roche, Sanofi and Pfizer. ROB--FIN is funded by AbbVie, Hospira, BMS, MSD, Pfizer, Roche and UCB. The Romanian Registry of Rheumatic Diseases (RRBR) uses unrestricted grants from AbbVie, Pfizer, Eli Lilly, Ewopharma, Nopvartis MSD, Roche, UCB, and BMS. Swiss Clinical Quality Management in Rheumatic Diseases (SCQM) database is sponsored by public and industrial support (http://scqm.ch/en/sponsorenTest/).; Lauper , K , Ludici , M , Mongin , D , Bergstra , S A , Choquette , D , Codreanu , C , Cordtz , R , De Cock , D , Dreyer , L , Elkayam , O , Hauge , E-M , Huschek , D , Hyrich , K L , Iannone , F , Inanc , N , Kearsley-Fleet , L , Kristianslund , E K , Kvien , T K , Leeb , B F , Lukina , G , Nordström , D C , Pavelka , K , Pombo-Suarez , M , Rotar , Z , Santos , M J , Strangfeld , A , Verschueren , P , Courvoisier , D S & Finckh , A 2022 , ' Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration ' , Annals of the Rheumatic Diseases , vol. 81 , no. 10 , pp. 1358-1366 . https://doi.org/10.1136/annrheumdis-2022-222586Test; 51602553-6c62-448e-8098-1972b2b975ea; http://hdl.handle.net/10138/349608Test; 000812373100001

الإتاحة: http://hdl.handle.net/10138/349608Test

View record in BASE

تنقيح النتائج